Restenosis: Is There a Pharmacologic Fix in the Pipeline?

Advances in Pharmacology

Volumn 39, Issue C, 1997, Pages 313-353

  Keiser, Joan A ^a   Uprichard, Andrew C G ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; GROWTH INHIBITOR; HEPARIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ANIMAL; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; GENE THERAPY; HUMAN; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHOTOTHERAPY; RECURRENT DISEASE; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANTIBODIES, MONOCLONAL; CORONARY DISEASE; CORONARY VESSELS; FIBRINOLYTIC AGENTS; GENE THERAPY; GROWTH INHIBITORS; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PHOTOTHERAPY; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE;

EID: 0030625167     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60075-7     Document Type: Article

References (210)

1. Abe J.I., Zhou W., Taguchi J.I., Takuwa N., Miki K., and Okazaki H. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdkl oligonucleotides in rat carotid artery. Biochem. Biophys. Res. Commun. 198 1 (1994) 16-24
2. Azuma H., Niimi Y., and Hamasaki H. Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan. Br. J. Pharmacol. 106 3 (1992) 665-671
3. Azuma H., Hamasaki H., and Niimi Y. Endothelin (ET-1) plays a role in the intimal hyperplasia after endothelial removal. Can. J. Physiol. Pharmacol. 72 Suppl. 1 (1994) 154
4. Barry W.L., and Sarembock I.J. Antiplatelet and anticoagulant therapy in patients undergoing percutaneous transluminal coronary angioplasty. Cardiol. Clin. 12 3 (1994) 535-571
5. Baumann D.S., Doblas M., Schonfeld G., Sicard G.A., and Daugherty A. Probucol reduces the cellularity of aortic intimal thickening at anastomotic regions adjacent to prosthetic grafts in cholesterol-fed rabbits. Arterioscler. Thromb. 14 (1994) 162-167
6. Bauters C., Van Belle E., Wernert N., Delcayre C., Thomas F., Dupuis B., Lablanche J.M., Bertrand M.E., and Swynghedauw B. Angiopeptin inhibits oncogene induction in rabbit aorta after balloon denudation. Circulation 89 5 (1994) 2327-2331
7. Beathard G.A. Percutaneous transvenous angioplasty in the treatment of vascular access stenosis. Kidney Int. 42 (1992) 1390-1397
8. Beigel Y., Zafrir N., Teplitzky Y., Neuman Y., Gavish D., Wurzel M., and Fainaru M. The effect of lovastatin on early restenosis. J. Clin. Pharmacol. 35 6 (1995) 599-605
9. Bendeck M.P., Zempo N., Clowes A.W., Galardy R.E., and Reidy M.A. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. 75 (1994) 539-545
10. Bendeck M.P., Irvin C., and Reidy M.A. Inhibition of matrix metalloprteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ. Res. 78 (1996) 38-43
11. Bennett M.R., and Schwartz S.M. Antisense therapy for angioplasty restenosis: Some critical considerations. Circulation 92 7 (1995) 1981-1993
12. Bennett M.R., Anglin S., McEwan J.R., Jagoe R., Newby A.C., and Evan G.I. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J. Clin. Invest. 93 2 (1994) 820-828
13. Bitazarian S.D., Currier J.W., Tsunekazu K., Haudenschild C.C., and Faxon D.P. Angiotensin II antagonism does not prevent restenosis after rabbit iliac angioplasty. Circulation 86 4 (1992) 1-187
14. Blakenworth D.H. Blood lipids and human atherosclerosis regression: The angiographic evidence. Curr. Opin. Lipidol. 2 (1991) 2324-2329
15. Bochaton-Piallat M.L., Gabbiani F., Redard M., Desmouliere A., and Gabbiani G. Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am. J. Pathol. 146 5 (1995) 1059-1064
16. Brack M., Ray S., Chauhan A., Fox J., Schofield P., and Harley A. Subcutaneous heparin and angioplasty restenosis prevention: Results of a multicentre randomised trial evaluating unfractionated heparin. Br. Heart J. 71 5 (1994) P29
17. Brown G., Albers J.J., Fisher L.D., Schaeffer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., and Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipopro-tein B. N. Engl. J. Med. 323 (1990) 1289-1298
18. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Regenass U., and Lydon N.B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 2558-2562
19. Burgess T.L., Fisher E.F., Ross S.L., Bready J.V., Qian Y.X., Bayewitch L.A., Cohen A.M., Herrera C.J., Hu S.S.F., Kramer T.B., Lott F.D., Martin F.H., Pierce G.F., Simonet L., and Farrell C. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. U.S.A. 92 9 (1995) 4051-4055
20. Carew T.E., Schwenke D.C., and Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7725-7729
21. Carrozza J.P., Kuntz K.R., Schatz R.A., Leon M., Goldberg S., Savage M., Fischman D., Senerchia C., Diver D.J., and Bairn D.S. Inter-series differences in the restenosis rate of Palmaz-Schatz coronary stent placement: Differences in demographics and post-procedure lumen diameter. Catheterization Cardiovasc. Diagn. 31 3 (1994) 173-178
22. Carter A.J., Laird J.R., Farb A., Kufs W., Wortham D.C., and Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J. Am. Coll. Cardiol. 24 5 (1994) 1398-1405
23. Casscells W. Migration of smooth muscle and endothelial cells, critical events in restenosis. Circulation 86 3 (1992) 723-729
24. Castronuovo Jr. J.J., Guss S.B., Mysh D., Sawhney A., Wolff M., and Gown A.M. Cytokine therapy for arterial restenosis: Inhibition of neointimal hyperplasia by gamma-interferon. Cardiovasc. Surg. 3 5 (1995) 463-468
25. Chang M.W., Barr E., Lu M.M., Seltzer J., Jiang Y.Q., Nabel G.J., Nabel E.G., Parmacek M.S., and Leiden J.M. Cytostatic gene therapy for vascular proliferra-tive disorders with a constitutively active form of the retinoblastoma gene product. Science 267 (1995) 520-522
26. Chang M.W., Barr E., Lu M.M., Barton K., and Leiden J.M. Adenovirus-mediated over-expression of the cyclin/cyclindependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96 5 (1995) 2260-2268
27. Chen S.J., Chen Y.F., Miller D.M., Li H., and Oparil S. Mithramyacin inhibit myointimal proliferation after balloon injury of the rat carotid artery in vivo. Circulation 90 5 (1994) 2468-2473
28. Chesebro J.H., Webster M.W., Reeder G.S., Mock M.B., Grill D.E., and Bailey K.R. Coronary angioplasty: Antiplatelet therapy reduces acute complications but not restenosis. Circulation 80 (1989) II-64
29. Choi E.T., Engel L., Callow A.D., Sun S., Trachtenberg J., Santoro S., and Ryan U.S. Inhibition of neointimal hyperplasia by blocking alpha-v-beta-3 integrin with a small peptide antagonist GpenGRGDSPCA. J. Vasc. Surg. 19 1 (1994) 125-134
30. Clowes A.W., and Karnovsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature (London) 265 (1977) 625-626
31. Clowes A.W., and Schwartz S.M. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ. Res. 56 (1985) 139-145
32. Clowes A.W., Reidy M.A., and Clowes M.M. Mechanisms of stenosis after arterial injury. Lab. Invest. 49 2 (1983) 208-215
33. Clowes A.W., Reidy M.A., and Clowes M.M. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle cell growth in the absence of endothelium. Lab. Invest. 49 (1983) 327-333
34. Clowes A.W., Clowes M.M., and Reidy M.A. Kinetics of cellular proliferation after arterial injury. III. Endothelial and smooth muscle cell growth in chronically denuded vessels. Lab. Invest. 54 (1986) 295-303
35. Clozel J.P., Hess P., Michael C., Schietinger K., and Baumgartner H.R. Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs. Hypertension (Dallas) 18 Suppl. 4 (1991) 1155-1159
36. Colomb G., Fishbein I., Banai S., Moscovitz D., Msihaly D., Gertz S.D., Gazit A., and Levitski A. Restenosis therapy by site-specific delivery of tyrphostins in animal models. Pharm. Res. 11 S10 (1994) 610
37. Cooke T., Sheahan R., Foley D., Reilly M., D'Arcy G., Jauch W., Gibney M., Gearty G., Crean P., and Walsh M. Lipoprotein (a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation 89 (1994) 1593-1598
38. Corcos T., David P.R., Val P.G., Renkin J., Dangoisse V., and Rapold H.G. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. Am. Heart. J 109 (1985) 926-931
39. Corsini A., Raiteri M., Soma M.R., Fumagalli R., and Paoletti R. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol. Res. 23 (1991) 173-180
40. Crawford N., Chajara A., Pfielgler G., El Gamal D., Brewer L., and Capron L. Targeting platelets containing electro-encapsulated iloprost to balloon injured aorta in rats. Thromb. Haemostasis 73 3 (1995) 535-542
41. Culp S.C., Zidar J.P., Jackman J.D., Phillips H.R., Overman A.B., and Stack R.S. An improved rabbit model of atherosclerosis. Circulation 86 4 (1992) 1-188
42. Cumnerland D.C., Gunn J., Tsikaderis D., Arafa S., and Ahsan A. Initial clinical experience of local drug delivery via a porous balloon during percutaneous coronary angioplasty. J. Am. Coll. Cardiol. 23 (1994) 186A
43. Currier J.W., and Faxon D.P. Restenosis after percutaneous transluminal angioplasty: Have we been aiming at the wrong target. J. Am. Coll. Cardiol. 25 2 (1995) 516-520
44. Daemen M.J., Lombardi A.P.D.M., Bosman F.T., and Schwartz S.M. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ. Res. 68 (1991) 450-456
45. Dorros G., Jaff M., Jain A., Dufek C., and Mathiak L. Follow-up of primary Palmaz-Schatz stent placement for atherosclerotic renal artery stenosis. Am. J. Cardiol. 75 1 (1995) 1051-1055
46. Douglas S.A., Louden C., Vickery-Clark L.M., Storer B.L., Hart T., Feurstein G.Z., Elliott J.D., and Ohlstein E.H. A role for endogenous endothelin-1 in neointimal formation after carotid artery balloon angioplasty: Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ. Res. 75 1 (1994) 190-197
47. Douglas S.A., Vickery-Clark L.M., Louden C., and Ohlstein E.H. Selective ETA receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointimal formation in the rat. Cardiovasc. Res. 29 5 (1995) 641-646
48. Dunlop P., Varty K., Hartshorne T., Bell P.R., Bolia A., and London N.J. Percutaneous transluminal angioplasty of infrainguinal vein graft stenosis: Long-term outcome. Br. J. Surg. 82 2 (1995) 204-206
49. Edelman E.R., and Karnovsky M.J. Contrasting effects of the intermittant and continuous administration of heparin in experimental restenosis. Circulation 89 2 (1994) 770-776
50. Edelman E.R., Nugent M.A., Smith L.T., and Karnovsky M.J. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J. Clin. Invest. 89 (1992) 465-473
51. Elliott J.M., Berdan L.G., Holmes D.R., Isner J.M., King III S.B., Keeler G.P., Kearney M., Califf R.M., and Topol E.J. One-year follow-up in the coronary angioplasty versus excisional atherectomy trial (CAVEAT I). Circulation 91 (1995) 2158-2166 for the CAVEAT Study Investigators
52. Emanuelsson H., Beatt K.J., Bagger J.P., Balcon R., Heikkila J., Piessen J., Schaeffer M., Suryapranta H., and Foegh M. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical but not angiographic restenosis. Circulation 91 6 (1995) 1689-1696
53. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33 (1992) 1569-1582
54. Endo A. Use of a monoclonal antibody directed against the platelet gyloco-protein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330 (1994) 956-961 EPIC Investigators
55. Epstein S.E., Speir E., Unger E.F., Guzman R.J., and Finkel T. The basis of molecular strategies for treating coronary restenosis after angioplasty. J. Am. Coll. Cardiol. 23 6 (1994) 1278-1288
56. Eriksen U.H., Amtorp O., Bagger J.P., Emanuelsson H., Foegh M., Henningsen P., Saunamaki K., Schaeffer M., Thayssen P., Orskov H., Kuntz R.E., and Popma J.J. Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am. Heart J. 130 1 (1995) 1-8
57. Faxon D.P. Mechanisms of angioplasty and pathophysiology of restenosis based on cell biology. In: Faxon D. (Ed). "Practical Angioplasty" (1993), Raven Press, New York 5-13
58. Faxon D.P. On behalf of the multicenter American research trial with cilazapril after angioplasty to prevent transluminal coronary obstruction and restenosis (MARCATOR) study group. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J. Am. Coll. Cardiol. 2 (1995) 362-369
59. Faxon D.P., and Currier J.W. Prevention of post-PTCA restenosis. Ann. N.Y. Acad. Sci. 748 (1995) 419-427
60. Faxon D.P., Weber V.J., Haudenschild C., Gottsman S.B., McGovern W.A., and Ryan T.J. Acute effects of transluminal angioplasty in three models of atherosclerosis. Arteriosclerosis (Dallas) 2 (1982) 125-133
61. Faxon D.P., Sanborn T.A., and Weber V.J. Restenosis following transluminal angioplasty in experimental atherosclerosis. Arteriosclerosis (Dallas) 4 (1984) 189-195
62. Faxon D.P., Spiro T.E., Minor S., Cote G., Douglas J., Gottlieb R., Califf R., Dorosti K., Topol E., Gordon J.B., and Ohmen M. Low molecular weight heparin in prevention of restenosis after angioplasty. Circulation 90 (1994) 908-914 the ERA Investigators
63. Ferns G.A.A., Forster L., Stewart-Lee A., Konneh M., Nourooz-Zadeh J., and Anggard E.E. Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 11312-11316
64. Ferrer P., Valentine M., Jenkins-West T., Weber H., Goller N.L., Durham S.K., Molloy C.J., and Moreland S. Oraly active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries. J. Cardiovasc. Pharmacol. 26 (1995) 908-915
65. Fischman D.L., Leon M.L., Bairn D.S., Schatz R.A., Savage M.P., Penn I., Detre K., Veltri L., Ricci D., Nobuyoshi M., Cleman M., Heuser R., Almond D., Teirstein P.S., Fish R.D., Colombo A., Brinker J., Moses J., Shaknovich A., Hirshfeld J., Bailey S., Ellis S.G., and Rake R. A randomised comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 331 (1994) 496-501 Goldberg, S. for the Stent Restenosis Investigators
66. Foegh M.L., Khirabadi B.S., Chambers E., Amamoo S., and Ramwell R.W. Inhibition of coronary artery transplant atherosclerosis in rabbits with angiopeptin, an octapeptide. Atherosclerosis (Shannon, Irel.) 78 (1989) 229-236
67. Foley D.P., Bonnier H., Jackson G., Macaya C., Shepherd J., and Vrolix M. Prevention of restenosis after coronary balloon angioplasty: Rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. Am. J. Cardiol. 73 14 (1994) 50D-61D
68. Fram D.B., Aretz T., Azrin M.A., Samady H., Gillam L.D., Sahatijan R., Waters D., and McKay R.G. Localized intramural drug delivery during balloon angioplasty using hydrogel-coated balloons and pressure-augmented diffusion. J. Am. Coll. Cardiol. 23 7 (1994) 1570-1577
69. Franklin S.M., and Faxon D.P. Pharmacologic prevention of restenosis after coronary angioplasty: Review of randomised clinical trials. Coronary Artery Dis. 4 (1993) 232-242
70. French B.A., Mazur W., Ali N.M., Geske R.S., Finnigan J.P., Rodgers G.P., Roberts R., and Raizner A.E. Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries and two models of coronary restenosis. Circulation 90 5 (1994) 2402-2413
71. Fry D., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., Connors R.W., and Bridges A.J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265 (1994) 1093-1095
72. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., Unemori E.N., Lark M.W., Amento E., and Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res. 75 (1994) 181-189
73. Geary R.L., Williams J.K., Golden D., Brown D.G., Benjamin M.E., and Adams M.R. Time course of cellular proliferation, intimal hyperplasia and remodeling following angioplasty in monkeys with established atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 34-43
74. Gershlick A.H., Spriggins D., Davies S.W., Syndercombe-Court Y.D., Timmins J., Timmis A.D., Rothman M.T., Layton C., and Balcon R. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. Br. Heart J. 71 1 (1994) 7-15
75. Gertz S.D., Gimple L.W., Banai S., Ragosta M., Powers E.R., Roberts W.C., Perez L.S., and Sarembock I.J. Geometric remodeling is not the principal pathogenetic process in restenosis after balloon angioplasty. Evidence from correlative angiographic-histomorphometric studies of atherosclerotic arteries in rabbits. Circulation 90 6 (1994) 3001-3008
76. Glagov S. Intimal hyperplasia, vascular remodeling and the restenosis problem. Circulation 89 6 (1994) 2888-2891
77. Gradus-Pizlo I., Wilensky R.L., March K.L., Fineberg N., Michaels M., Sandusky G.E., and Hathaway D.R. Local delivery of biodegradable microparticles containing colchicine or a colchicine analog: Effects on restenosis and implications for catheter-based drug delivery. J. Am. Coll. Cardiol. 26 6 (1995) 1549-1557
78. Grainger D., Kirchenlohr H., Metcalfe J., Weissberg P., Wade D., and Lawn R. Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science 260 (1993) 1655-1658
79. Gray R.J., Horton K.M., Dolmatch B.L., Runback J.H., Anaise D., Aquino A.O., Currier C.B., Light J.A., and Sasaki T.M. Use of Wallstents for hemodialysis access-related venous stenosis and occlusions untreatable with balloon angioplasty. Radiology 195 2 (1995) 479-484
80. Grines C.L., Rizik D., Levine A., Schreiber T., Gangadharan V., Ramos R., Choksi N., Gangadharan C., and Timmis G.C. Colchicine angioplasty restenosis trail (CART). Circulation 84 (1991) II-365
81. Groves H.M., Kinlough-Rathbone R.L., and Richardson M. Platelet interaction with damaged rabbit aorta. Lab. Invest. 40 (1979) 194-200
82. Groves P.H., Banning A.P., Penny W.J., Newby A.C., Cheadle H.A., and Lewis M.J. The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. Cardiovasc. Res. 30 1 (1995) 87-96
83. Gruentzig A.R., King III S.B., Schlumpf M., and Siegenthaler W. Nonoperative dilation of caronary-artery stenosis. N. Engl. J. Med. 301 (1979) 61-73
84. Guo J.P., Milhoan K.A., Tuan R.S., and Lefer A.M. Beneficial effect of SPM-5185, a cysteine-containing nitric oxide donor, in rat carotid artery intimal injury. Circ. Res. 75 1 (1994) 77-84
85. Guzman L.A., Farrel C.L., Popti C.E.J., Dicorleto P.E., and Topol E.J. Despite in vivo cellular and nuclear uptake, antisense oligonucleotides do not have a significant anti-proliferative effect after vascular injury. Circulation 90 4 (1994) I-147 Part 2
86. Guzman R.J., Hirschowitz E.A., Brody S.L., Crystal R.G., and Epstein S.E. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. U.S.A. 91 22 (1994) 10732-10736
87. Hagemenas F.C., Pappu A.S., and Illingsworth D.R. The effect of simvastatin on plasma lippoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolemia. Eur. J. Clin. Invest. 20 (1990) 150-157
88. Hansson G.K. Immunological control mechanisms in plaque formation. Basic Res. Cardiol. 89 Suppl. 1 (1994) 41-46
89. Hayry P., Myllarniemi M., Aavik E., Alatalo S., Aho P., Yilmaz S., Raisanen-Sokolowski A., Cozzone G., Jameson B.A., and Baserga R. Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J. 9 13 (1995) 1336-1344
90. Hearn J., Donohue B., Ba'alkabi H., Douglas J.S., King S.B., Lembo N.J., Roubin G.S., and Sgoutas D.S. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am. J. Cardiol. 69 (1992) 736-739
91. Hehrlein C., Gollan C., Doenges K., Metz J., Riessen R., Fehsenfeld P., von Hodenberg E., and Kuebler W. Low-dose radioactive endovascular stems prevent smooth muscle cell proliferation and neointimal hyperplasia in rabbits. Circulation 92 6 (1995) 1570-1575
92. Herrman J.P.R., Hermans W.R.M., Vos J., and Serruys P.W. Pharmacological approaches to the prevention of restenosis following angioplasty. Drugs 46 (1993) 18-52
93. Hillegass W.B., Ohman E.M., and Califf R.A. Restenosis: The clinical issues. In: Topol E.J. (Ed). "Textbook of Interventional Cardiology" (1994), Saunders, Philadelphia 415-435
94. Holmes D.R., Simpson J.B., Berdan L.G., Gottlieb R.S., Leya F., Keeler G.P., Califf R.M., and Topol E.J. Abrupt closure: The CAVEAT I experience. J. Am. Coll. Cardiol. 26 (1995) 1494-1500 for the CAVEAT I Investigators
95. Huber K.C., Schwartz R.S., Edwards W.D., Camrud A.R., Bailey K.R., Jorgenson M.A., and Holmes D.R. Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model. Am. Heart J. 125 3 (1993) 695-701
96. Ide S., Kondoh M., Satoh H., and Karasawa A. Anti-proliferative effects of benidi-pine hydrochloride in porcine cultured vascular smooth muscle cells and in rats subjected to balloon catheter-induced endothelial denudation. Biol. Pharm. Bull. 17 5 (1994) 627-631
97. Ide S., Kondoh M., Satoh H., and Karasawa A. Inhibitor action of benidipine on balloon catheterization-induced intimal thickening of the carotid artery in rats. Jpn. J. Pharmacol. 65 1 (1994) 89-92
98. Illingworth D.G. HMG CoA reductase inhibitors. Curr. Opin. Lipidol. 2 (1991) 24-30
99. Indolfi C., Esposito G., DiLorenzo E., Rapacciuolo A., Feliciello A., Porcellini A., Avvedi-mento V.E., Condorelli M., and Chiariello M. Smooth muscle cell proliferation is proportional to the degree of balloon injury in a rat model of angioplasty. Circulation 92 (1995) 1230-1235
100. Irons C.E., Flynn M.A., Mok L.L., and Reynolds E.E. Endothelin and platelet-derived growth factor enhance arachadonic acid release and DNA synthesis in vascular smooth muscle cells. Am. J. Physiol. 270 6 (1996) C1642-C1646 Pt.1
101. Isner J.M., Walsh K., Symes J., Piecek A., Takeshita S., Lowry J., Rossow S., Rosenfield K., Weir L., Brogi E., and Schainfeld R. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 91 (1995) 2687-2692
102. Jang Y., Guzman L.A., Lincoff M., Gottsauner-Wolf M., Forudi F., Hart C.E., Courtman D.W., Ezban M., Ellis S.G., and Topol E.J. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 92 (1995) 3041-3050
103. Jawien A., Bowen-Pope D., Lindner V., Schwartz S.M., and Clowes A.W. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest. 89 (1992) 507-511
104. Karas S.P., Santoian E.C., and Gravanis M.B. Restenosis following coronary angioplasty. Clin. Cardiol. 14 (1991) 791-801
105. Kaul U., Chandra S., Bahl V.K., Sharma S., and Wasir H.S. Enalapril for prevention of restenosis after coronary angioplasty. Indian Heart J. 45 6 (1994) 469-473
106. Kawamura M., Terashita Z.I., Okida H., Imura Y., Shino A., Nakao M., and Nishikawa K. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. J. Pharmacol. Exp. Ther. 266 3 (1993) 1664-1669
107. Kimura T., Shinoda E., Sato Y., Yokoi H., Tamura T., Nakagawa Y., Nosaka H., and Nobuyoshi M. Difference in acute gain (AG) and late loss (LL) relationship among three different new angioplasty devices (NAD). Circulation 90 4 (1994) I-59 Part 2
108. Klauss V., Blasini R., and Regar E. Mechanisms of coronary in-stent restenosis: neointimal proliferation or stent compression? Serial assessment by intracoronary ultrasound. Circulation 88 (1993) 1-598
109. Kobayashi M., Ishida F., Takhashi T., Taguchi K., Watanabe K., Ohmura I., and Kamei T. Preventive effects of MK-733 (Simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits. Jpn. J. Pharmacol. 49 (1989) 125-133
110. Kohno M., Horio T., Yokokawa K., Yasunari K., Kurihara N., and Takeda T. Endothelin modulates the mitogenic effect of PDGF on glomerular mesangial cells. Am. J. Physiol. 266 (1994) F894-F900
111. Kuntz R.E., and Bairn D.S. Defining coronary restenosis: newer clinical and angio-graphic paradigms. Circulation 88 (1993) 1310-1323
112. Labhasetwar V., Song C., Humphrey W., Shebuski R., and Levy R.J. Nanoparticles for site specific delivery of U-86983 in restenosis in pig coronary arteries. Proc. Int. Symp. Control Relat. Bioact. Mater. 22 (1995) 182-183
113. Lafont A., Guzman L.A., Whitlow P.L., Goormasti C.M., Cornhill J.F., and Chilsom G.M. Restenosis after experimental angioplasty. Circ. Res. 76 (1995) 996-1002
114. Lambert C.R., Taylor S., and Smith T. Pressure and volume control for local drug-delivery catheters: Development of a new microprocessor-controlled system. Coronary Artery Dis. 5 2 (1994) 163-167
115. Lee J.S., Adrie C., Jacob H.J., Roberts Jr. J.D., Zapol W.M., and Bloch K.D. Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury. Circ. Res. 78 (1996) 337-342
116. Levy R.J., Golomb G., Trachy J., Labhasetwar V., Song D., and Topol M.E. Strategies for treating arterial restenosis using polymeric controlled release implants. In: Gebelein C.G., and Carraher C.E. (Eds). "Biotechnology and Bioactive Polymers" (1994), Plenum, London 342
117. Levy R.J., Labhasetwar V., Song C., Lerner E., Chen W., Vyavahare N., and Qu X. Polymeric drug delivery systems for treatment of cardiovascular calcification, arrhythmias and restenosis. J. Controlled Release 36 1-2 (1995) 137-147
118. Lindner V., Lappi D.A., Baird A., Majack R.A., and Reidy M.A. Role of basic fibroblast growth factor in vascular lesion formation. Circ. Res. 68 (1991) 106-113
119. Lindner V., Fingerle J., and Reidy M.A. Mouse model of arterial injury. Circ. Res. 73 (1993) 792-796
120. Liu M.W., Roubin G.S., Robinson K.A., Black A.J.R., Hearn J.A., Siegel R.J., and King III S.P. Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 81 (1990) 1089-1093
121. Losordo D.W., Pickering J.G., Takeshita S., Lecler C.G., Gal D., Weir L., Kearney M., Jekanowski J., and Isner J.M. Use of the rabbit ear artery to serially assess foreign protein secretion after site-specific arterial gene transfer in vivo. Circulation 89 2 (1994) 785-792
122. Lundergan C.F., Foegh M.L., and Ramwell P.W. Peptide inhibition of myointimal proliferation by angiopeptin, a somatostatin analogue. J. Am. Coll. Cardiol. 17 6 (1991) 132B-136B
123. Luo H., Nishoka T., Eigler N., Tabak S., and Siegel R.J. Chronic vessel constriction is an important mechanism of restenosis after balloon angioplasty: An intravascular ultrasound study. Circulation 90 4 (1994) 1-61 Part 2
124. Majesky M.W., and Schwartz S.M. Smooth muscle diversity in arterial wound repair. Toxicol. Pathol. 18 4 (1990) 554-559
125. Majesky M.W., Giachelli C.M., Reidy M.A., and Schwartz S.M. Rat carotid neointimal smooth muscle cells reexpress a developmentally regulated mRNA phenotype during repair of arterial injury. Circ. Res. 71 4 (1992) 759-768
126. March K.L., Mohanraj S., Ho P.P.K., Wilensky R.L., and Hathaway D.R. Biodegradable microspheres containing a colchicine analogue inhibit DNA synthesis in vascular smooth muscle cells. Circulation 89 5 (1994) 1929-1933
127. March K.L., Madison J.E., and Trapnell B.C. Pharmacokinetics of adenoviral-mediated gene delivery to vascular smooth muscle cells: Modulation by polyxamer 407 and implications for cardiovascular gene therapy. Hum. Gene Ther. 6 1 (1995) 41-53
128. Margolis J.R., Krauthamer D., Litvak F., Rothbaum D.A., and Untereker W.J. Six month follow-up of excimer laser coronary angioplasty registry patients. J. Am. Coll. Cardiol. 17 (1991) 218A
129. Mazur W., Ali N.M., Raizner A.E., and French B.A. Coronary restenosis and gene therapy. Tex. Heart Inst. J. 21 1 (1994) 104-111
130. Mazur W., Ali N.M., Grinstead W.C., Schulz D.G., Raizner A.E., and French B.A. Lipofectin-mediated versus adenovirus-mediated gene transfer in vito and in vivo: Comparison of canine and procine modelsystems. Coronary Artery Dis. 5 9 (1994) 779-786
131. Mazur W., Ali N.M., Grinstead W.C., Schulz D.G., Raizner A.E., and French B.A. Does the angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous angioplasty? Results of the MERCATOR study: A multicenter, randomized, double-blinded placebo-controlled trial. Circulation 86 (1992) 100-110 MERCATOR Study Group
132. Moncada S., Palmer R.M.J., and Higgs E.A. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43 (1991) 109-142
133. Moore S. Thromboatherosclerosis in normolipemic rabbits: A result of continued endothelial damage. Lab. Invest. 29 (1979) 478-487
134. Morishita R., Gibbons G.H., Ellison K.E., Nakajima M., Von Der Leyen H., Zhang L., Kaneda Y., Ogihara T., and Dzau V.J. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J. Clin. Invest. 93 4 (1994) 1458-1464
135. Morishita R., Gibbons G.H., Kaneda Y., Ogihara T., and Dzau V.J. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin Bl and CDC 2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 149 1 (1994) 13-19
136. Morishita R., Gibbons G.H., Horiuchi M., Ellison K.E., Nakajima M., Zhang L., Kaneda Y., Ogihara T., and Dzau V.J. A gene therapy strategy using a transcription factor decoy of E2F binding sites inhibits smooth muscle cell proliferation in vivo. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 5855-5859
137. Muller D.W.M., Ellis S.G., and Topol E.J. Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions. J. Am. Coll. Cardiol. 17 6 (1991) 126B-131B
138. Muller D.W.M., Ellis S.G., and Topol E.J. Experimental models of coronary artery restenosis. J. Am. Coll. Cardiol. 19 2 (1992) 418-432
139. Murray A., and Hunt T. "The Cell Cycle," (1993), Freeman, New York 106
140. Nabel E.G., Yang Z., Plautz G., Frough R., Zhan X., Haudenschild C.C., Maciag T., and Nabel G.J. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature (London) 362 (1993) 844-846
141. Nabel E.G., Yang Z., Liptay S., San H., Gordon D., and Haudenschild C.C. Recombinant platelet derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo. J. Clin. Invest. 91 (1993) 1822-1829
142. Nabel E.G., Shum L., Pompili V.J., Yang Z., San H., Shu H.B., Liptay L., Gold L., Gordon D., Derynck R., and Nabel G.J. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperplasia. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 10759-10763
143. Nabel E.G., Pompili V.J., Plautz G.E., and Nabel G.J. Gene transfer and vascular disease. Cardiovasc. Res. 28 (1994) 713-719
144. Nair R.J., Cao W., and Morris R.E. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Immunol. Lett. 47 (1995) 171-174
145. Newman K.D., Dunn P.F., Owens J.W., Schulick A.H., Virmani R., Sukhova G., Libby P., and Dichek D.A. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation and neointimal hyperplasia. J. Clin. Invest. 96 (1995) 2955-2965
146. Nikkari S.T., Geary R.L., Hatsukami T., Ferguson M., Forough R., Alpers C.E., and Clowes A.W. Expression of collagen, interstitial collagenase and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy. Am. J. Pathol. 148 3 (1996) 777-783
147. Nunes G.L., Sgoutas D.S., Redden R.A., Sigman S.R., Gravanis M.B., King S.B., and Berk III B.C. Combination of vitamins C and E alters the response to coronary balloon injury in the pig. Arterioscler. Thromb. Vasc. Biol. 15 1 (1995) 156-165
148. Nyamekye I., Anglin S., Bown S., Bishop C., and McEwan J. Inhibition of intimal hyperplasia by photodynamic therapy in the rat carotid artery model of angioplasty restenosis. Br. Heart J. 71 Suppl.5 (1994) 17
149. Nyamekye I., Anglin S., McEwan J., Macrobert A., Bown S., and Bishop C. Photodynamic therapy of normal and balloon-injured rat carotid arteries using 5-amino-levulinic acid. Circulation 91 2 (1995) 417-425
150. O'Brien E.R., Alpers E.C., Stewart D.K., Ferguson M., Tran N., Gordon D., Bensitt E.P., Hinohara T., Simpson J.B., and Schwartz S.M. Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ. Res. 73 (1993) 223-231
151. Ohnishi H., Yamaguchi K., Shimada S., Suzuki Y., and Kumagai A. A new approach to treatment of atherosclerosis and trapidil as an antagonist to platelet derived growth factor. Life Sci. 28 14 (1981) 1641-1646
152. Ohno T., Gordon D., San H., Pompili V., Imperiale M.J., Nabel G.J., and Nabel E.G. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265 (1994) 781-784
153. Okamato S., Inden M., Setsuda M., Konishi T., and Nakano T. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am. Heart J. 123 (1992) 1439-1444
154. O'Keefe J.H., Giorgi L.V., Hartzler G.O., Good T.H., Ligon R.W., and Webb D.L. Effects of diltiazem on complications and restenosis after coronary angioplasty. Am. J. Cardiol. 67 (1991) 373-376
155. Onaka H., Hirota Y., Kita Y., Tsuji R., Ishii K., Ishimura T., and Kawamura K. The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Jpn. Circ. J. 58 2 (1994) 100-106
156. Parish M.A., Grossi E.A., Baumann F.G., Asai T., Rifkin D.B., Colvin S.B., and Galloway A.C. Effects of a single administration of fibroblast growth factor on vascular wall reaction to injury. Ann. Thorac. Surg. 59 4 (1995) 948-954
157. Pastore C.J., Isner J.M., Bacha P.A., Kearney M., and Pickering J.G. Epidermal growth factor receptor-targeted cytotoxin inhibits neointimal hyperplasia in vivo: Results of local versus systemic administration. Circ. Res. 77 3 (1995) 519-529
158. Pepine C.J., Hirshfeld J.W., Macdonald R.G., Henderson M.A., Bass T.A., Goldberg S., Savage M.P., Vetrovec G., Cowley M., Taussig A.S., Whitworth H.B., Margolis J.R., Hill J.A., Bove A.A., and Jugo R. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation 81 (1990) 1753-1761 for the M-HEART Group
159. Planes A., Vochelle N., Mazas C., Zucman J., Landais A., Pascariello J., Weill D., and Butel J. Prevention of postoperative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb. Haemostasis 60 (1988) 407-410
160. Post M.J., Borst C., and Kuntz R.E. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. Circulation 89 (1994) 2816-2821
161. Powell J.S., Clozel J.P., Muller R.K.M., Kuhn H., Hefti F., Hosang M., and Baumgartner H.R. Inhibitor of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245 (1989) 186-188
162. Pratt R.E., and Dzau V.J. Pharmacologic strategies to prevent restenosis. Circulation 93 (1996) 848-852
163. Prescott M.F., Webb R.L., and Reidy M.A. Angiotensin converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist: Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am. J. Pathol. 139 (1991) 1291-1296
164. Puka C.L.A., Castellot J.J., Wright T.C., Caleb B.L., and Karnovsky M.J. Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Regul. 1 5 (1990) 435-443
165. Rakugi H., Wang D.S., Dzau V.J., and Pratt R.E. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 90 1 (1994) 449-455
166. Rao G.N., and Berk B.C. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ. Res. 70 (1992) 593-599
167. Riessen R., and Isner J.M. Prospects for site-specific delivery of pharmacologic and molecular therapies. J. Am. Coll. Cardiol. 23 5 (1994) 1234-1244
168. Ryan M.J., Emig L.E., Hicks G.W., Ramharack R., Spahr M.A., Kreick J.S., Brammer D.W., Chien A.J., and Reiser J.A. Vascular localization of lipoprotein(a) in a monkey model of vessel injury. Arterioscler. Thromb. Vasc. Biol. 17 (1997) (in press)
169. Sahni R., Maniet A.R., Voci G., and Banka V.S. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am. Heart J. 121 (1991) 1600-1608
170. Sarembock I.J., LaVeau P.J., Sigal S.L., Timms I., Sussman J., Haudenschild C., and Ezekowitz M.D. Influence of inflation pressure and balloon size on the development of intimal hyperplasia after balloon angioplasty. A study in the atherosclerotic rabbit. Circulation 80 4 (1989) 1029-1040
171. Savage M.P., Goldberg S., Bove A.A., Deutsch E., Vetrovec G., Macdonald R.G., Bass T., Margolis J.R., Whitworth H.B., Taussig A., Hirshfeld Cowley J.W.M., Hill J.A., Marks R.G., Fischman D.L., Handberg E., Herrmann H., and Pepine C.J. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty: Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 92 11 (1995) 3194-3200
172. Schneider J.E., Berk B.C., Gravanis M.B., Santoian E.C., Cipolla G.D., Tarazona N., Lassegue B., and King III S.B. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. Circulation 88 (1993) 628-637
173. Schwartz R.S., Bourassa M.G., Lesperance J., Aldridge H.E., Kazim F., and Salvatori V.A. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 318 (1988) 1714-1719
174. Schwartz R.S., Murphy J.G., Edwards W.D., Camrud A.R., Vliestra R.E., and Holmes D.R. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 82 (1990) 2190-2200
175. Serruys P.W., Strauss B.H., Beatt K.J., Bertrand M.E., and Puel J. Angiographic follow-up after placement of a self-expanding coronary artery stent. N. Engl. J. Med. 324 (1991) 13-17
176. Serruys P.W., Jaegewre P., Kiemeniej F., Macaya C., Rutsch W., Heyndrickx G., Emanuels-son H., Marco J., Legrand V., Materne P., Belardi J., Sigwart U., Colombo A., Goy J.J., van den Heuvel P., Delcan J., and Morel M.A. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 331 (1994) 489-495 for the Benestent Study Group
177. Serruys P.W., Herrman J.P.R., Simon R., Rutsch W., Bode C., Laarman G.J., Van Dijk R., Van den Bos A.A., Umans V.A., Fox W.M.K.A.A., Close P., and Deckers J.W. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N. Engl. J. Med. 333 12 (1995) 757-763
178. Shi Y., Fard A., Galeo A., Hutchinson H.G., Vermani P., Dodge G.R., Hall D.J., Shaheen F., and Zalewski A. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 90 2 (1994) 944-951
179. Shimotakahara S., and Mayberg M.R. Gamma irradiation inhibits neointimal hyperplasia in rats after arterial injury. Stroke 25 2 (1994) 424-428
180. Simons M., Edelman E.R., DeKeyser J.L., Langer R., and Rosenberg R.D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (London) 359 (1992) 67-70
181. Simpson J.B., Bairn D.S., Hinohara T., Cowley M.J., and Smucker M.L. Restenosis of de novo lesions in native coronary arteries following directional coronary atherectomy: Multicenter experience. J. Am. Coll. Cardiol. 17 (1991) 346A the US Directional Coronary Investigator Group
182. Singh J.P., Rothfuss K.J., Wiemicki T.R., Lacefield W.B., Kurtz W.L., Brown R.F., Brune K.A., Bailey D., and Dube G.P. Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: Implications in the treatment of restenosis after angioplasty. J. Am. Coll. Cardiol. 23 3 (1994) 665-671
183. Smith E.B. The influence of age and atherosclerosis on the chemistry of aortic intima. J. Atheroscler. Res. 5 (1965) 241-248
184. Snow A.D., Bolendar R.P., Wight T.N., and Clowes A.W. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am. J. Pathol. 137 (1990) 313-330
185. Sollott S.J., Cheng L., Pauly R.R., Jenkins G.M., Monticone R.E., Kuzuya M., Froehlich J.P., Crow M.T., Lakatta E.G., Rowinsky E.K., and Kinsella J.L. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J. Clin. Invest. 95 4 (1995) 1869-1876
186. Soma M.R., Donetti E., Parolini C., Mazzini G., Ferrari C., Fumagalli R., and Paoletti R. HMG CoA reductase inhibitors: In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler. Thromb. 13 (1993) 571-578
187. Soma M.R., Donetti E., Parolini C., Sirtori C.R., Fumagalli R., and Franceschini G. Recombinant apolipoprotein A-I-Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ. Res. 76 3 (1995) 405-411
188. Speidel C.M., Eisenberg P.R., Ruf W., Edgington T.S., and Abendschein D.R. Tissue factor mediates prolonged procoagulation activity on the luminal surface on balloon-injured aortas in rabbits. Circulation 92 (1995) 3323-3330
189. Steele P.M., Chesebro J.H., and Stanson A.W. Balloon angioplasty: Natural history of the pathophysiologic response to injury in the pig model. Circ. Res. 57 (1985) 105-112
190. Stone G.W., Rutherford B.D., and Hartzler G.O. A randomized trial of corticoids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. Catheterization Cardiovasc. Diagn. 18 (1989) 227-231
191. Tenda K., Salkawa T., Maeda T., Sato Y., Niwa H., Inoue T., Yonemochi H., Maruyama T., Shimoyama N., Aragaki S., Hara M., and Takaki R. The relationship between serum lipoprotein (a) and restenosis after initial elective percutaneous translumi-nal coronary angioplasty. Jpn. Circ. J. 57 (1993) 789-795
192. Texter M., Lees R.S., Pitt B., Dinsmore R.E., and Uprichard A.C. The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovasc. Drugs Ther. 7 2 (1993) 273-282
193. Tiell M.L., Sussman I.I., Gordon P.B., and Sanders R.N. Suppression of fibroblast proliferation in vitro and of neointimal hyperplasia in vivo by the tratzolopyrimidine, trapidil. Artery (Fulton, Mich.) 12 (1983) 33-50
194. Timms I.D., Tomaszewski J.E., and Shiansky-Goldberg R.D. Effects on nonanticoag-ulant heparin (Astenose) on restenosis after balloon angioplasty in the atherosclerotic rabbit. J. Vasc. Interv. Radiology 6 3 (1995) 365-378
195. Topol E.J., Ellis S.G., Cosgrove D.M., Bates E.R., Muller D.W., Schork N.J., Schork M.A., and Loop F.D. Analysis of coronary angioplasty practice in the United States with an insurance-claims database. Circulation 87 (1993) 1489-1497
196. Topol E.J., Leya F., Pinkerton Whitlow C.A., Hofling B., Simonton C.A.P.L., Masden R.R., Serruys P.W., Leon M.B., Williams D.O., King III S.B., Mark D.B., Isner J.M., Holmer Jr. D.R., Ellis S.G., Lee K.L., Keeler G.P., Berdan L.G., Hinohara T., and Califf R.M. A comparison of direction atherectomy with coronary angioplasty in patients with coronary artery disease. N. Engl. J. Med. 329 4 (1993) 221-227 for the CAVEAT Study Group
197. Topol E.J., Califf R.M., Weisman H.F., Ellis S.G., Tcheng J.E., Worley S., Ivanhoe R., George B.S., Fintel D., and Weston M. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 343 8902 (1994) 881-886
198. Vesselinovitch D. Animal models and the study of atherosclerosis. Arch. Pathol. Lab. Med. 112 (1988) 1011-1017
199. Von Der Leyen H., Gibbons G.H., Morishita R., Lewis N.P., Zhang L., Nakajima M., Kaneda Y., Cooke J., and Dzau V.J. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 1137-1141
200. Waksman R., Robinson K.A., Crocker I.R., Gravanis M.B., Cipolla G.D., and King III S.B. Endovascular low-dose irradiation inhibits neointima formation after coronary artery balloon injury in swine: A possible role for radiation therapy in restenosis prevention. Circulation 91 5 (1995) 1533-1539
201. Waksman R., Robinson K.A., Crocker I.R., Gravanis M.B., Palmer S.J., Wang C., Cipolla G.D., and King III S.B. Intracoronary radiation before stent implantation inhibits neointima formation in stented porcine coronary arteries. Circulation 92 6 (1995) 1383-1386
202. Waltenberger J., Kovalenko M., Boehmer F., Gazit A., Hombach V., and Levitzki A. Characterization of receptor-tyrosine-kinase-inhibitors: Selectivity as a molecular basis for the treatment of restenosis. Eur. Heart J. 15 (1994) 427 (abstr.)
203. Weintraub W.S., Boccuzzi S.J., Klein J.L., Kosinski A.S., King S.B., Ivanhoe R., Cedarholm J.C., Stillabower M.E., Talley J.D., and DeMaio S.J. Lack of effect of lovastatin on restenosis after coronary angioplasty. N. Engl. J. Med. 331 20 (1994) 1331-1337
204. Whitworth H.B., Roubin G.S., Hollman J., Meier B., Leimgruber P.P., and Douglas J.S. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. J. Am. Coll. Cardiol. 8 (1986) 1271-1276
205. Wiedermann J.G., Marboe C., Amols H., Schwartz A., and Weinberger J. Intracoronary irradiation markedly reduces neointimal proliferation after balloon angioplasty in swine: Persistent benefit at 6-month follow-up. J. Am. Coll. Cardiol. 25 6 (1995) 1451-1456
206. Wong S.C., Leon M.B., and Popma J.J. New device angioplasty: The impact on restenoisis. Coronary Artery Dis. 4 (1993) 243-253
207. Wong S.C., Bairn D.S., Schatz R.A., Teirstein P.S., King S.B., Curry R.C., Heuser R.R., Ellis S.G., Cleman M.W., and Overlie P. Immediate and late outcomes after stent implantation in saphenous vein graft lesions: The multicenter U.S., Palmaz-Schatz stent experience. J. Am. Coll. Cardiol. 26 3 (1995) 704-712
208. Yellai S.S., and Schatz R.A. Indications and use of the Palmaz-Schatz coronary stent. Cardiol. Clin. 12 4 (1994) 651-663
209. Zempo N., Koyama N., Kenagy R.D., Lea H.J., and Clowes A.W. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 28-33
210. Zhu B.Q., Sievers R.E., Sun Y.P., Isemberg W.M., and Parmley W.W. Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J. Cardiovasc. Pharmacol. 19 (1992) 246-255